0
₹0 0
Nextgen Biotech

Call us:

menu

Carbozest (150mg / 450mg) - Carboplatin Injection

Carbozest (150mg / 450mg) - Carboplatin Injection

Carbozest is a platinum-based chemotherapy injection used to treat various cancers, including ovarian and lung cancers. It works by interfering with the DNA replication of cancer cells, thereby stopping their growth and multiplication.

Select the packing Size:

Choose Quantity:

-
+
+ Add To Cart
Add to wishlist
Share
Description Product Details
General Information:
Generic Name: Carboplatin
Brand Name: Carbozest
Packing: Single-use vial
Strengths Available: 150mg / 450mg
Manufacturer: Zee Laboratories Ltd
Form: Intravenous Injection
Category: Antineoplastic agent (Alkylating agent – platinum compound)
Prescription Status: Rx only (prescription required)
Product Introduction:
Carbozest contains Carboplatin, a second-generation platinum compound used as an anti-cancer agent. Known for its reduced nephrotoxicity compared to cisplatin, Carbozest is administered intravenously and is an essential component of various chemotherapy regimens in oncology.
Uses:
Carbozest is used in the treatment of:
  1. Ovarian cancer (initial and recurrent treatment)
  2. Non-small cell lung cancer (NSCLC)
  3. Small cell lung cancer (SCLC)
  4. Head and neck cancers
  5. Brain tumors (e.g., glioblastoma – off-label)
  6. Testicular and bladder cancers (off-label indications)
Storage Instructions:
  1. Store between 2°C to 8°C (refrigerated conditions)
  2. Protect from light and freezing
  3. Use the diluted solution immediately or as per guidelines
  4. Keep out of reach of children
How It Works (Mechanism of Action):
Carboplatin forms DNA crosslinks, which inhibit DNA synthesis and transcription, ultimately leading to apoptosis (programmed cell death) in rapidly dividing cancer cells. It is cytotoxic and non-specific to the cell cycle phase.
Side Effects:
Common side effects:
  1. Nausea and vomiting
  2. Hair loss
  3. Fatigue
  4. Low white blood cell or platelet counts
  5. Electrolyte imbalances
  6. Changes in taste
Severe side effects:
  1. Myelosuppression (severe anemia, neutropenia, thrombocytopenia)
  2. Allergic reactions (fever, rash, hypotension)
  3. Hearing loss (ototoxicity)
  4. Kidney or liver function impairment
  5. Severe infections due to immune suppression
Dosage (Typical Recommended Dose):
  1. Flat dosing (e.g., ovarian cancer): 300–360 mg/m² IV every 4 weeks
  2. AUC-based dosing (Calvert formula):
    Dose (mg) = Target AUC × (GFR + 25)
    Typical AUC: 5–7.5
  3. Dosage should be individualized based on renal function and blood counts
Method of Administration:
  1. Administered as an intravenous infusion over 15–60 minutes
  2. Must be diluted in 5% Dextrose or 0.9% Sodium Chloride before use
  3. Should only be given by a qualified healthcare professional in a clinical setting
Precautions:
  1. Monitor complete blood count (CBC) regularly
  2. Avoid use in pregnancy and breastfeeding
  3. Use caution in patients with kidney dysfunction
  4. Hydrate adequately to support renal function
  5. Do not mix with aluminum-containing IV sets
Drug Interactions:
  1. Aminoglycosides or other nephrotoxic drugs may enhance kidney toxicity
  2. Live vaccines should be avoided due to immunosuppression
  3. Increased bone marrow suppression when combined with other myelosuppressants
  4. Use caution with loop diuretics (ototoxicity risk)
Aller gies:
  1. Contraindicated in individuals allergic to Carboplatin, cisplatin, or platinum compounds
  2. Watch for signs of hypersensitivity: rash, wheezing, fever, chills, or anaphylaxis
  3. Discontinue treatment if allergic reactions occur
Overdose Information:
  1. Symptoms: profound bone marrow suppression, renal toxicity, electrolyte imbalance
  2. No specific antidote available
  3. Treatment is supportive, including blood transfusions and infection management
  4. Hospitalization may be required
Missed Dose Instructions:
  1. Carbozest is administered in a clinical setting, so missed doses are rescheduled by the healthcare provider
  2. Patients should not self-administer or alter dosing schedules under any circumstance
Additional Notes:
  1. Regular kidney, liver, and hematological assessments are essential during treatment
  2. Patients should use effective contraception during and for several months after treatment
  3. Avoid exposure to infections; practice good hygiene during treatment
  4. Inform the doctor of all current medications and supplements before starting Carbozest

In The Same Category

Cart